Somatic Mutation
15
5
5
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 15 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (15)
UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations
iSITE: Investigation of Somatic Alterations in Tumours of the Eye
Linking Somatic Mutation Rate With Baseline Exposure in East Palestine
Molecular Diagnosis of Systemic Autoinflammatory Diseases
Somatic Mosaicism in Twins Discordant for Childhood Cancer
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
SMS - Study of Somatic Mutations Using Genome Sequencing
Development of Polygenic Risk Scores in Colon Cancer Patients Through the Study of Ancestry and Diversity in Genetic Maps of the Brazilian Population - ORIGEM Project
SMS 2: Impact of Cancer Therapy on the Somatic Mutational Landscape of Normal Tissues
Somatic Mutation in Chronic Liver Disease
Exploring the Landscape of Somatic Mutations in Human Tissue
A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study
Lynch Syndrome Can be Diagnosed Just From Somatic Mismatch Repair Mutation
A Retrospective Pharmacokinetics and Pharmacogenomics Research of Imatinib in Gastrointestinal Stromal Tumor Treatment